

China In-Depth Overview

Quick Start Guide

July 2022



What is China In-Depth?

China In-Depth provides market intelligence and detailed market insights for the biopharma and biotech industries supported by detailed primary and secondary research. This product helps gauge the commercial outlook and optimize clinical development, subpopulation targeting, physician messaging, and long-term strategy plans in China.

Report highlights:

- ✓ 10-year, annualized drug-level forecasts split by urban and rural China for all commercially relevant drugs and subpopulations
 - ✓ Includes the new Market Forecast Dashboard enabling you to visualize key forecast trends and data by zone, population, and forecast parameters
- ✓ Epidemiology including rural and urban populations
- ✓ Current treatment insights (including Traditional Chinese Medicine) and comprehensive coverage of emerging therapies
- ✓ Insights into complex and dynamic access and reimbursement environment in China
- ✓ Primary market research with 5 thought-leading physician interviews and a survey of 50-75 physicians per disease and extensive secondary research by Clarivate experts

Clarivate DRG Platform Login

To login to the DRG Clarivate platform, click on - <https://authentication.decisionresourcesgroup.com/login/Solutions>

Clarivate™ | DRG

About Us | Contact Us

Welcome to Clarivate DRG

Whether you are a new or existing user, enter your email address

Having problems? Email DRG.support@clarivate.com

*You may be asked for a password if your company is not integrated with the DRG platform

© 2022 Clarivate. | [Privacy policy](#) | [Terms of use](#)

Work email address

Work email address

Get started

Get started using Disease, Company & Drug Insights Platform

The screenshot shows the Clarivate DRG platform dashboard. At the top, the logo 'Clarivate | DRG' is on the left, and 'About Us' and 'Contact Us' links are on the right. The main heading is 'Welcome [redacted] from Clarivate'. Below this is a note: 'Hover over any link to learn more about each product platform. Green check marks indicate partial or full content is available to you as part of your current subscription.' A button labeled 'Have a question' is followed by a red box containing the number '2' and the text 'Please contact us'.

The dashboard is divided into three main sections:

- Understand the Market**
 - Disease, Company & Drug Insights** (Annotated with a red box and the number '3')
 - ✓ Disease, Company & Drug Insights Platform
 - Disease Insights
 - Epidemiology
 - Biosimilars
 - Company and Drug Insights
 - Medtech**
 - ✓ Medtech Insights Platform
 - Market Insights (Medtech 360)
 - Brand Tracking (Pricetrack & Marketrack)
 - US Medical Supply Distribution
 - US Market Access Insights**
 - ✓ US Market Access Insights Platform
 - Health Plan Analysis
 - Market Overviews
 - Market Overview Interactive Database
 - National MCO Analyzer
 - Power Profiles
- Optimize Access**
 - US Formulary Data & Analytics** (By Fingertip Formulary)
 - ✓ Account Management Dashboard
 - ✓ Fingertip Accounts
 - ✓ Fingertip Alerts
 - ✓ Fingertip Analytics
 - ✓ Fingertip Home Page (Legacy Platforms)
 - ✓ Fingertip Restrictions
 - ✓ Fingertip Validation Tool
 - ✗ Fingertip PolicyTrack
 - US Lives Data & Analytics**
 - ✓ Employer Vantage (2020 Data)
 - ✓ Employer Vantage (2021 Data)
 - ✓ Integrated Payer Platform
 - ✓ Managed Market Surveyor Suite (Including Pharmacy Benefit Evaluator)
 - Global Market Access**
- Engage Customers**
 - Sales Enablement**
 - ✓ Fingertip Publisher
 - Commercial Targeting**
 - ✓ Healthbase
 - ✓ Medtech Insights Platform
 - Commercial Targeting (Procedure Finder)
 - ✗ Field Force Navigator (FFN)
 - Digital/Multichannel Stakeholder Engagement**
 - ✓ Digital Insights Platform
 - Multichannel Physician Engagement
 - Multichannel Patient Engagement
 - Multichannel Payer Engagement

1.
Go to:
<https://authentication.decisionresourcesgroup.com/login>

2.
Upon login screen, use your work e-mail address and password to login. If you experience any issues, please contact healthcare.support@clarivate.com

3.
Click on the “Disease, Company & Drug Insights” link.

Disease, Company & Drug Insights Home Page

The screenshot shows the Clarivate DRG Home Page. The header includes the Clarivate logo and 'DRG' on the left, and a 'Browse All' link with a dropdown arrow, a notification bell with a red '1', a chat bubble, and a user profile icon on the right. The main banner has a purple background with a molecular structure pattern and the text 'Hi [redacted] what are you looking for today?'. Below the banner is a search bar with the text 'arma' and a green search button. A tooltip for 'China In-Depth' is open, showing details about geographic coverage, forecasts, primary research, epidemiology, and emerging therapy coverage. The tooltip also lists 'Recently Viewed' items: Type 2 Diabetes, Non-Small-Cell Lung Cancer, Biosimilars, Psoriasis, Breast Cancer, Non-Hodgkin's Lymphoma an..., and Migraine. A green button at the bottom of the tooltip says 'Browse diseases and topics'. Below the tooltip, there are three main sections: 'Multichannel Engagement', 'Patient Populations', and 'Treatment Analysis'. The 'Patient Populations' section lists 'Epidemiology' and 'Epidemiology Data Slicer'. The 'Treatment Analysis' section lists 'Current Treatment Physician Insights', 'Unmet Need', 'Treatment Algorithms Claims Data Analysis', and 'Treatment Sequencing'. At the bottom left, there is a 'Market Access' section with 'Access & Reimbursement'. A blue question mark icon is in the bottom right corner.

Clarivate™ | DRG

Hi [redacted] what are you looking for today?

1

China In-Depth
Assess commercial opportunities and optimize your strategy with comprehensive China pharmaceutical market data and insights

Geographic Coverage: China

Forecast: 10-year, annualized, drug-level sales and patient share

Primary Research: China-specific interviews with thought-leading experts and survey of physician specialists

Epidemiology: Diagnosed prevalent and drug-treated cases

Emerging Therapy Coverage: Key Phase II, III and PR products and select preclinical and Phase I products

Recently Viewed | Clear

- Type 2 Diabetes
- Non-Small-Cell Lung Cancer
- Biosimilars
- Psoriasis
- Breast Cancer
- Non-Hodgkin's Lymphoma an...
- Migraine

[Browse diseases and topics](#)

[China In-Depth](#) [Learn more](#)

[Company & Drug Insights](#)

[Cortellis Supply Chain Network](#)

Market Access

- [Access & Reimbursement](#)

Patient Populations

- [Epidemiology](#)
- [Epidemiology Data Slicer](#)

Treatment Analysis

- [Current Treatment Physician Insights](#)
- [Unmet Need](#)
- [Treatment Algorithms Claims Data Analysis](#)
- [Treatment Sequencing](#)

?

1. Hover over “Disease Landscape & Forecast / Learn more” link to view product highlights as well as links to recently viewed reports. Select Browse diseases and topics to jump to the China In-Depth landing page.

China In-Depth Report Directory and Filters Page

Search Options:

The screenshot shows the Clarivate DRG interface for the China In-Depth report directory. The page is divided into several sections:

- Filters (1):** A sidebar on the left containing filters for Ownership, Product type, and Geography.
- Quick Links (2):** A list of therapeutic areas including Autoimmune & Inflammation, Biosimilars, Cardiovascular, Central Nervous System, Infectious Disease, Metabolic Disorders, and Oncology.
- Search (4):** A search bar at the top left of the main content area with the placeholder text "Type a disease or topic".
- Recently viewed (3):** A section showing a list of recently viewed topics, including Breast Cancer, Non-Small-Cell Lung Cancer, Biosimilars, and Type 2 Diabetes.
- What's covered? (5):** A dropdown menu for the "Breast Cancer" topic, showing a list of sub-topics with status indicators (green checkmarks for owned content, red padlocks for not subscribed content).

The "What's covered?" dropdown for "Breast Cancer" includes the following sub-topics:

- At a Glance (green checkmark)
- Landscape & Forecast (green checkmark)
- Epidemiology (green checkmark)
- Current Treatment (green checkmark)
- Unmet Need (green checkmark)
- Access & Reimbursement (green checkmark)
- Geographic Focus: China (red padlock)
- Meet the Team (green checkmark)

1. Add Ownership, Product Type or Geography filters to narrow your search.

2. Use quick links to jump to therapy areas of interest

3. Select recently viewed disease topic or select from directory.

4. Type in partial word search to bring up possible matches.

5. Select "What's covered?" to see what content is owned (green checks) vs not subscribed (red padlocks).

China In-Depth Report

The screenshot displays the 'Breast Cancer - China In-Depth (China)' report page. The top navigation bar includes links for Home, Diseases, and various report sections. The left sidebar (labeled '1') shows the 'Table of contents' with a search bar and a list of report sections. The main content area (labeled '2') features a large report cover with the Clarivate logo, the title 'Breast cancer', and the analyst's name 'Vikrant Anjna, M. Pharm.'. The right sidebar contains a 'Downloads' section with links to various report attachments and a 'Meet the Team' section with a profile of Vikrant Anjna.

1. Table of contents highlights include:

- Executive Summary
- Disease Background
- Unmet Need
- China Biopharma Background
- Disease-specific Epidemiology / Patient Demographics
- Market Access of Current Disease-specific Therapies
- Current Disease Management
- Emerging Therapies
- Forecast / Market Outlook

2. The full report as well as the accompanying Executive Summary PPT slide deck and the Market Forecast Assumptions and Market Forecast Dashboard Excel files can be downloaded by selecting the file(s) of interest.

Market Forecast Assumptions

Forecast Data By Regimen

Sales (in MM USD)	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031
Total Breast Cancer											
Total Sales	2,023.8	2,133.6	1,853.1	2,281.0	2,478.6	2,768.1	3,014.3	3,315.6	3,715.0	3,832.4	3,816.3
Chemotherapy agents / regimens	133.3	90.4	55.6	47.5	48.8	49.8	51.1	52.4	54.0	55.5	56.1
AC (doxorubicin + cyclophosphamide)	1.8	1.9	1.4	0.4	0.4	0.5	0.5	0.5	0.5	0.5	0.5
Cyclophosphamide	0.7	0.7	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2
Cyclophosphamide Brand	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Cyclophosphamide Generic	0.6	0.6	0.1	0.1	0.2	0.2	0.2	0.2	0.2	0.2	0.2
Doxorubicin	1.2	1.2	1.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3
Doxorubicin Brand	-	-	-	-	-	-	-	-	-	-	-
Doxorubicin Generic	1.2	1.2	1.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3
AC-docetaxel (doxorubicin + cyclophosphamide + docetaxel)	3.3	1.3	0.9	0.6	0.6	0.6	0.6	0.7	0.7	0.7	0.7
AC-paclitaxel (doxorubicin + cyclophosphamide + paclitaxel)	9.8	7.6	5.6	3.6	3.7	3.8	3.9	4.0	4.1	4.3	4.4
AP (doxorubicin + paclitaxel)	2.2	1.5	1.2	0.9	1.0	1.0	1.0	1.1	1.1	1.1	1.2
AT (doxorubicin + docetaxel)	3.2	1.2	0.9	0.5	0.5	0.6	0.6	0.6	0.6	0.6	0.6
Capecitabine	2.0	2.0	2.0	2.0	2.0	1.9	1.9	2.0	2.0	2.0	2.2
Extended adjuvant capecitabine	1.7	1.8	1.9	1.9	2.0	2.2	2.2	2.3	2.4	2.4	2.5
CMF (cyclophosphamide + methotrexate + 5-fluorouracil)	1.4	1.4	0.4	0.3	0.3	0.4	0.4	0.4	0.4	0.4	0.4
D-Carbo (docetaxel + carboplatin)	5.1	2.8	2.5	1.0	1.0	1.0	1.1	1.1	1.1	1.2	1.2
Docetaxel	6.1	1.7	0.9	1.0	1.0	1.0	1.0	1.1	1.1	1.1	1.2
Gemcitabine	1.2	0.5	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.4
Doxorubicin	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
EC (epirubicin + cyclophosphamide)	3.4	3.5	0.8	0.9	0.9	0.9	0.9	1.0	1.0	1.0	1.0

1. The Market Forecast Assumptions (MFA) consists of 3 informational tabs (Contents, Contact Us, and Methodology) and multiple disease-specific tabs (Epidemiology, Forecast Summary, Drug Price, Regimen dosing (where applicable) and (sub)population tabs).

2. Forecast Summary tab includes drug forecasts by:

- Drug Sales
- Price Per Treated Day or Price per Cycle
- Patient Share
- Treated Population

3. Quickly convert currency from USD to RMB.


4. Expand views to include:

- 1 - Drug classes
- 2 - Specific brands/molecules
- 3 - Generic and biosimilar

Market Forecast Dashboard (introduced in Q2 2022!)

The Market Forecast Dashboard (MFD) interactive Excel tool helps you to understand, interpret, explore, and visualize key forecast outputs from Clarivate's patient-based market forecast for a given indication. This is a supplement to the Market Forecast Assumptions file and enables you to visualize key forecast trends and data by zone (urban/rural), population, forecast parameter (e.g., sales, patient share). You can customize the data displayed in various prefab charts and dynamic tables using slicers. To access the tool, please click the file in the downloads section on the right-hand side panel for a given report.

1. Navigate between tabs for different forecast components and use filters to customize analyses and visualizations.



Alerts Request

Clarivate™ | DRG | Biopharma | Search within Biopharma

Home / **My Favorite Topics** | View My Notifications

Diseases & Other Topics | Medtech

Start typing a disease or topic

Autoimmune & Inflammation

- ☐ **Dermatology**
 - ☐ Acne
 - ☐ Actinic Keratosis
 - ☐ Alopecia
 - ☐ Atopic Dermatitis/Atopic Eczema
 - ☐ Dermatitis/Eczema
 - ☐ Hidradenitis Suppurativa
 - ☐ Psoriasis
 - ☐ Urticaria

Respiratory

- ☐ Acute Respiratory Distress Syndrome
- ☐ Allergic Rhinitis
- ☐ Asthma
- ☐ Chronic Obstructive Pulmonary Disease
- ☐ Cystic Fibrosis
- ☐ Idiopathic Pulmonary Fibrosis
- ☐ Obstructive Sleep Apnea
- ☐ Sarcoidosis

Rheumatology

- ☐ Axial Spondyloarthritis
- ☐ Juvenile Idiopathic Arthritis
- ☐ Osteoarthritis
- ☐ Rheumatoid Arthritis
- ☐ Scleroderma (Systemic Sclerosis)
- ☐ Sjogren's Syndrome

My Favorites

Email Preferences

☐ Email me when there is updated content or new content published matching my favorites

Save Settings

1.
To request email alerts of China In-Depth report key updates, select the bell icon.

2.
Select the disease markets that you are subscribed to, then select the “Email Preferences” checkbox, then select the “Save Settings” button.

Support Requests

Breast Cancer Notifications Off

At a Glance Landscape & Forecast Epidemiology Current Treatment Unmet Need Access & Reimbursement Geographic Focus: China Meet The Team

Table of contents Expand all

Search within Content

Overview

Breast Cancer - China In-Depth (China)

Breast Cancer - China In-Depth (China)

Breast Cancer - China In-Depth (China)

Last updated 22 June 2022

DISPLAY All 0 0 1

1 of 199

Clarivate™

China In-Depth

Breast cancer

Analyst: Vikrant Anjna, M. Pharm.

Published: June 2022

To navigate, use right/left arrows on your keyboard, or the page numbers/arrows within the viewer tool. Alternatively, use the full screen feature for additional navigational options.

Downloads

MAIN CONTENT

Breast Cancer - China In-Depth (China) Attachment

Breast Cancer - China In-Depth - Market Forecast Assumptions Attachment

Executive Summary Deck - China In-Depth - 2022 Attachment

Breast Cancer - China In-Depth - Market Forecast Dashboard Attachment

ADDITIONAL FILES

Breast Cancer - China In-Depth (China) Table of Contents

1

Meet the Team

Vikrant Anjna, M. Pharm.

Ask the Expert View Bio

2 ?

1. If you have additional questions or training/support requests, select “Ask the Expert” or “Contact Us” located under the “?” (Resources & updates) icon.



Have a Question?

healthcare.support@clarivate.com
clarivate.com

About Clarivate

Clarivate™ is a global leader in providing solutions to accelerate the lifecycle of innovation. Our bold mission is to help customers solve some of the world's most complex problems by providing actionable information and insights that reduce the time from new ideas to life-changing inventions in the areas of science and intellectual property. We help customers discover, protect and commercialize their inventions using our trusted subscription and technology-based solutions coupled with deep domain expertise. For more information, please visit clarivate.com.

© 2022 Clarivate. All rights reserved. Reproduction or redistribution of Clarivate content, including by framing or similar means, is prohibited without the prior written consent of Clarivate. Clarivate and its logo, as well as all other trademarks used herein are trademarks of their respective owners and used under license.